文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

Eplontersen联合或不联合背景TTR稳定剂治疗ATTR-CM的3期试验二次分析

Eplontersen with and without background transthyretin stabilizers in transthyretin amyloid cardiomyopathy: secondary analysis of a phase 3, randomized controlled trial.
PubMed 文献 · Nat Med · 2026-08-30

基于CARDIO-TTRansform 3期试验的预设二次分析,纳入1432例ATTR-CM患者,随机接受eplontersen 45mg每4周或安慰剂治疗至140周,基线57%使用TTR稳定剂。主要复合终点受基线稳定剂使用修饰(Pinteraction=0.017):未用稳定剂者获益(RR=0.71,95%CI 0.54-0.93,P=0.012),用稳定剂者无额外获益(RR=1.14,95%CI 0.85-1.53,P=0.39);安全谱良好。

要点

  • 未用TTR稳定剂者,eplontersen降低主要复合终点风险(RR=0.71)。
  • 已用TTR稳定剂者,eplontersen未显示额外临床获益(RR=1.14)。
  • 基线稳定剂使用显著修饰eplontersen疗效(Pinteraction=0.017)。

核心结论

  • eplontersen对未接受背景TTR稳定剂的ATTR-CM患者有临床意义获益,对已用稳定剂者无额外获益。

研究设计与样本

  • CARDIO-TTRansform 3期随机对照试验的预设二次分析,纳入1432例ATTR-CM患者(女135例,男1297例),1:1随机接受eplontersen 45mg每4周或安慰剂至140周。

主要发现

  • 主要复合终点(心血管死亡和复发性心血管事件)受基线稳定剂使用修饰(Pinteraction=0.017)。
  • 未用稳定剂者:RR=0.71,95%CI 0.54-0.93,P=0.012。
  • 用稳定剂者:RR=1.14,95%CI 0.85-1.53,P=0.39。
  • eplontersen安全谱良好,与基线是否使用稳定剂无关。

临床怎么用

  • 临床决策时需考虑患者基线是否使用TTR稳定剂,未用者可能从eplontersen获益更多。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) therapies include both TTR gene silencers and TTR stabilizers. The role of TTR gene silencers added to background TTR stabilizer therapy is unknown, and the effects of silencer treatment in the absence of stabilizer use are unclear. In the CARDIO-TTRansform study, 1,432 patients (n = 135 (9.4%) women and n = 1,297 (90.6%) men) with ATTR-CM were randomized (1:1) and treated with the antisense oligonucleotide eplontersen (45 mg every 4 weeks) that targets TTR or with placebo for up to 140 weeks. At baseline, 57% of the patients were taking TTR stabilizers. In the overall study, treatment with eplontersen did not reduce the primary composite endpoint. Here, in a prespecified analysis, we show that the primary endpoint (a composite of cardiovascular mortality and recurrent cardiovascular events) was modified by baseline stabilizer use (Pinteraction = 0.017). Benefits were observed in those patients not on stabilizers at baseline (rate ratio (RR) = 0.71, 95% confidence interval (CI) 0.54 to 0.93, P = 0.012), whereas no benefits were observed in those on stabilizers at baseline (RR = 1.14, 95% CI 0.85 to 1.53, P = 0.39). The safety profile of eplontersen was favorable, irrespective of baseline stabilizer use. Treatment with eplontersen versus placebo demonstrated a clinically meaningful benefit among patients not receiving background stabilizers but provided no additional clinical benefit in those on background stabilizer therapy. These findings of a strong treatment effect modification may offer insight for therapeutic decision-making in clinical practice. ClinicalTrials.gov registration: NCT04136171 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. García-Pavía P, Cappelli F, Davis MK, et al. Eplontersen with and without background transthyretin stabilizers in transthyretin amyloid cardiomyopathy: secondary analysis of a phase 3, randomized controlled trial. Nat Med. 2026. PMID: 42742182. doi:10.1038/s41591-026-04670-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。